Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01403038 · ClinicalTrials.gov registry record · Phase 1
An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females
A Phase 1 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 1
- Development phase
- 216
- Enrollment target
NCT01403038 is a Phase 1 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 216 participants.
The verdict
NCT01403038, a Phase 1 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 216 participants
- Enrollment target
Study Summary
This is an open-label Phase 1 study in healthy premenopausal females evaluating the effects of different dosing regimens of elagolix on ovarian activity, ovulation, and ovarian reserve and to assess the effect of elagolix on selected endocrine/hormone levels.
Interventions
- DRUG Elagolix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01403038
The ClinicalTrials.gov registry entry for NCT01403038 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Elagolix is the first listed.
NCT01403038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01403038 about?
NCT01403038 is a clinical study titled "An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females". This is an open-label Phase 1 study in healthy premenopausal females evaluating the effects of different dosing regimens of elagolix on ovarian activity, ovulation, and ovarian reserve and to assess the effect of elagolix on selected endocrine/hormone levels.
What is the current status of trial NCT01403038?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 216 participants. The study started on 2011-06. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01403038?
The interventions under investigation include: Elagolix (DRUG).
Who is sponsoring clinical trial NCT01403038?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.